Polihexanide

In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approximately 50%, IL-31, a major driver of itch, by nearly 68%, and IL-4, an important inflammatory cytokine, by 16.7% Findings support Turn’s approach of acting earlier in the inflammatory process, before inflammation becomes fully established WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03, selectively reduces several important inflammatory signals associated with inflammatory skin disease. The study, published in Life , showed that pretreatment with GX-03 reduced IL-36α and IL-36γ release by approximately 50%. IL-36 is an important early signal in the inflammatory cascade and helps amplify inflammation in the skin. GX-03 also reduced IL-31 by nearly 68%. IL-31 is closely associated with itch in inflammatory skin diseases such as atopic dermatitis. In addition, IL-4, another important inflammatory cytokine involved in the immune response, was reduced by 16.7%. Importantly, IL-13 was essentially unchanged, suggesting that GX-03 did not suppress every inflammatory signal measured, but instead produced a selective pattern of cytokine reduction. These biological changes were accompanied by a 66% reduction in clinical dermatitis severity in GX-03-pretreated animals compared with untreated controls. “This publication provides important new biological evidence about GX-03,” said Bradley Burnam, Chief Executive Officer of Turn Therapeutics. “In-vivo, GX-03 strongly reduced IL-36, a key early driver of the inflammatory cascade, as well as IL-31, a major driver of itch. It also reduced IL-4, an important inflammatory signal. What is particularly interesting is when this occurred. Rather than targeting inflammation only after it is already established, GX-03 was present before the challenge and substantially reduced the inflammatory response that followed skin challenge. We believe this supports a fundamentally different approach: modifying the local skin environment upstream, before the inflammatory cascade takes hold.” The timing of the intervention is an important part of the study. Many current therapies for atopic dermatitis are designed to block inflammatory pathways after disease and inflammation are already established. In this study, researchers applied GX-03 before exposing the skin to a standardized bacterial challenge known to trigger atopic dermatitis-like inflammation. They then measured the inflammatory response that developed afterward. Animals pretreated with GX-03 developed substantially less severe dermatitis and showed significant reductions in IL-36α, IL-36γ, IL-31 and IL-4. The study therefore provides a different experimental perspective on inflammatory skin disease by examining whether modifying the skin environment can change the intensity and pattern of the inflammatory response. The study evaluated 40 mice that received either no pretreatment or four days of topical GX-03 before standardized Staphylococcus aureus exposure. Following predefined exclusions, 18 animals in each group were included in the final analysis. GX-03 pretreatment reduced mean clinical disease severity from a vIGA-AD score of 2.44 in untreated animals to 0.83, representing a 66.0% reduction. IL-36α expression decreased by 49.9%, IL-36γ by 50.9%, IL-31 by 67.7%, and IL-4 by 16.7%. IL-13 did not differ significantly between the groups. No local irritation, dryness, redness, barrier disruption or other adverse skin findings were observed during the GX-03 pretreatment period. The publication, titled “Effects of Extended-Release Polyhexanide on Inflammatory Cytokine Expression and Disease Severity Following Staphylococcus aureus Exposure in a Murine Dermatitis Model,” was co-authored by Bradley Burnam, Chief Executive Officer of Turn Therapeutics, and Stephen D. Bresnick, M.D., an independent researcher. The study was conducted at Altogen Labs under an IACUC-approved protocol and builds upon Turn Therapeutics’ previously published research in the Journal of Dermatological Treatment . About GX-03 GX-03 is Turn Therapeutics’ proprietary, non-systemic topical investigational therapy currently in clinical development for atopic dermatitis. GX-03 is designed to act locally in the skin, where Turn is investigating whether modifying the local skin environment can reduce important inflammatory signals associated with disease while avoiding broad systemic immune suppression. The newly published findings provide in-vivo evidence that GX-03 is associated with selective reductions in IL-36, IL-31 and IL-4 following a standardized skin challenge. GX-03 is currently being evaluated in a randomized, double-blind, vehicle-controlled clinical trial in atopic dermatitis. About Turn Therapeutics Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics’ lead investigational topical candidate and is being developed as a targeted, non-systemic treatment for atopic dermatitis. Citation Burnam B, Bresnick S. Effects of Extended-Release Polyhexanide on Inflammatory Cytokine Expression and Disease Severity Following Staphylococcus aureus Exposure in a Murine Dermatitis Model. Life . 2026. DOI: 10.3390/life16081369 Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise. Contacts Turn Therapeutics Investor & Media Contact Sasha Damouni The Damouni Group Sasha@turntherapeutics.com

VIV SELECT CHINA 2026 亚洲国际集约化畜牧展览会（上海） 8月19-21日丨上海世博展览馆 做外贸生意来VIV，让订单源源不断 共赴 VIV SELECT CHINA 2026展会之约！ 精准获客，高效成交，直面决策者 持续为您提升品牌声量 展位火爆销售中 参展锁定外贸商机增长动能 8月相聚上海！ 展商推荐 天津中升挑战生物科技有限公司 Tianjin Speerise Challenge Biotechnology CO., LTD. 2号馆 H2D2311 展位号 2026/8/19-21  相约上海 欢迎新老朋友前来洽谈合作 01 FIRST 公司简介 天津市中升挑战生物科技有限公司（简称：挑战动保）成立于2002年，公司专注于动物保健领域，聚焦食品及伴侣动物健康。挑战动保以创新驱动发展，构建药物研发、生产到应用的全链条体系，涵盖小分子原料药及制剂、生物大分子预防及治疗药物、体外检测试剂（IVD）全系产品，是大多数国内规模养殖企业的核心动保合作伙伴，并拓展服务网络至东南亚、中东、非洲等地区，全球化布局初具规模。 依托“农业农村部兽药制剂创制重点实验室”、“天津市企业技术中心”、“动物用生化制药技术工程中心”、“天津市动物专用化学合成原料及制剂企业重点实验室”等研发平台，挑战动保2013~2023年猪用化药新药获批数量全国第一，产品开发水平稳居行业领先地位。获得“国家高新技术企业” “天津市科技小巨人领军企业”、“国家科学技术进步二等奖”等荣誉，先后入围“国际未来农业食品行业百强榜”②、“天津市民营企业100强”③、“全国化药制剂TOP15”④、“全国化药制剂企业销售前十”⑤榜单。伴随宠物经济崛起，伴侣动物业务实现快速增长。 挑战动保总部基地集研发、生产、工业展示与科普教育于一体，以智能、绿色理念赋能产业升级。秉持“呵护动物健康，助力食品安全”使命，矢志成为受业界推崇的创新型动保企业，为实现民族兽药的高质量发展努力奋斗。① 数据来源：《中国兽药信息网》、《新猪派》整理② 数据来源：35斗③ 数据来源：第十二届天津民营经济健康发展工程发布会 ④数据来源：新牧网“兽药制剂TOP15企业盘点”； ⑤数据来源：兽药产业发展报告（2024年度）附录。 Tianjin Speerise Challenge Biotechnology Co., LTD. (Abbreviation:Challenge Animal Health) was established in 2002. The company focuses on animal health, food and companion animal health. Challenge Animal Health drives development with innovation, build a full-chain industrial system from drug R & D, production to application, covering small molecule raw materials and preparations, biological macromolecules for prevention and treatment, and in vitro detection (IVD) products. It is the core animal protection partner of most domestic scale breeding enterprises, and expands its service network to Southeast Asia, Middle East, Africa and other regions. The global layout has begun to take shape. Relying on provincial R & D platforms such as“ the Key Laboratory of Veterinary Drug Preparation Innovation (Ministry of Agriculture and Rural Affairs),“Tianjin City Enterprise Technology Center","Animal Biochemical Pharmaceutical Technology Engineering Center","Tianjin City Key Laboratory of Animal Chemical Synthesis Raw Materials and Preparations Enterprise," the number of approved new chemical drugs for pigs ranked first in China① from 2013 to 2023, and the product development level remained in the leading position in the industry. It won honors such as "National High-tech Enterprise"、"Tianjin City Science and Technology Little Giant Leading Enterprise" and "Second Prize of National Science and Technology Progress Award". It has been shortlisted in the list of "Top 100 International Future Agricultural Food Industry"②, "Top 100 Private Enterprises in Tianjin City"③ and "TOP 15 National Chemical Preparations"④. With the rise of pet economy, companion animal business has achieved rapid growth. The headquarters base of Challenge Animal Health to integrate R & D, production, industrial display and science popularization education, and enable industrial upgrading with intelligent and green concepts. Adhering to the mission of " Care For Animal Health and Contribute To Food Safety ", we are determined to be an innovative animal health enterprise that is respected by the industry and strive to achieve high-quality development of ethnic veterinary drugs.   ① Data sources:《China Institute of Veterinary Drug Control》and 《New Pig Pie》 collation; ② Data sources:35 Dou; ③ Data sources:The Press Conference of the 12th Tianjin Private Economy Healthy Development Project; ④ Data sources:Xin Mu Net "Review of the Top 15 Veterinary Drug Formulation Companies"; ⑤Annual Report on Development of Veterinary Medicine Industry in China(2024) appendix; 公司地址：天津市西青区张家窝工业园区安泽道6号 NO.6,Anze Road,Zhangjiawo Industrial Zone,Xiqing District,Tianjin 服务热线：（86）22-87980458                       公司网址：www.tjtzdb.com 电子信箱：service@tjtzdb.com  2 SECOND 产品介绍 （1）挑战诺康——恩诺沙星注射液（20%）           CHALLENGE NuoKang-Enrofloxacin Injection(20%) 恩诺沙星为氟喹诺酮类畜禽专用广谱杀菌药，对敏感菌有明显的抗菌后效应。本品肌内注射吸收迅速而完全，生物利用度猪为90.56％；在动物体内广泛分布，能在白细胞蓄积达血浆浓度的140倍，用于治疗猪敏感菌引起的乳房炎-子宫炎-无乳综合症（MMA）（数据来源于农业农村部标准说明书）。 （2）多康——鸡传染性法氏囊病精制蛋黄抗体 Antibodies Extracted from Chinken Egg-Yolk against Infectious Bursal Disease 经广泛病料采集，分离纯化当前流行毒株，制备高免鸡蛋。经酸化萃取、高速离心、超滤等现代生产工艺，结合HOF多重灭活技术，既可提纯卵黄中的免疫球蛋白，又减少了产品污染的可能性。大量临床试验表明，效价稳定、疗效确实、保存期长、使用方便，不影响胴体品质。 （3）挑战泰瑞美——泰拉霉素注射液           Tinamecin-Tulathromycin Injection 抗菌活性高，用量少（2.5mg/kg.wt），注射后药物广泛分布，17分钟药物浓度即可达到峰值；且消除缓慢，单一剂量可持续整个疗程。 （4）挑战沙米——沙咪珠利溶液    CHALLENGE Saomizuril-Ethanamizuril Solution 国家一类新兽药，全新三嗪类化合物，对解决球虫耐药性难题，维护动物健康提供了有力保障。同时，其较短的休药期可减少药物残留对动物和食品安全的影响。 （5）挑战优盾——盐酸聚六亚甲基双胍溶液           Poly (hexamethylenebiguanide)hydrochloride Solution 盐酸聚六亚甲基双胍溶液的核心有效成分为聚六亚甲基双胍盐酸盐（PHMB），是一种细胞膜活性抗菌剂，结构中的甲基胍基团使聚合物呈正电性，与菌体表面负电荷的各类细菌、病毒吸附，从而抑制分裂，使其丧失活性。该消毒剂对细菌繁殖体有很好的杀灭作用，对真菌和分歧杆菌以及某些亲水性病毒有很好的杀灭效果。 （6）媒可约——烯丙孕素内服溶液 Altrenogest-Altrenogest Oral Solution 用于批次生产过程中，既可优化养猪管理，同步母猪发情，实现全进全出，又能够有效阻断疾病的水平传播。 （7）复倍喜——盐酸溴己新可溶性粉  Furbromxine-Bromhexine Hydrochloride Soluble Powder 具有祛痰解表、有效防治动物呼吸道疾病的功效。在兽医临床中，可单独用于黏液堵塞呼吸道为主要特征的呼吸道疾病的治疗；也可与多种抗生素联合应用，起到协同增效的作用，休药期0天（数据来源于农业农村部标准说明书）。 （8）梦不同——孟布酮注射液/粉  Menbutong-Menbutone Injection/Powder 具有刺激胃肠消化液分泌的作用，适用于猪、马、牛、绵羊、山羊和犬多种动物。其中对于仔猪消化不良，母猪消化不良、食欲减退、便秘腹胀等胃肠机能障碍疾病作用十分明显，也可预防产褥热引起的消化不良，辅助治疗肠炎、中毒性肝功能受损、肝营养不良以及肝退行性疾患（如脂肪肝），既可单独使用，也可作为辅助治疗用药或与其他药物联合用药。 （9）挑战康壮——复方布他磷注射液 Compound Butaphosphan Injection 专为动物设计的矿质元素补充剂，主要成分为布他磷与维生素B12，可通过静脉/肌注的方式为动物提供必要的营养补充，促进动物机体快速恢复到正常状态。 （10）禽腺病毒（I群4型）卵黄抗体 Fowl Adenovirues（Group I Serotype 4）Extracted Egg-yolk Antibodies 用于预防禽腺病毒（I群4型）引起的疾病。产品中和抗体效价不低于1∶256，接种后的保护期为168h，具有抗体效价高、特异性强等特点，能够快速为鸡体提供被动免疫保护。 （11）普瑞巴林内服溶液 Pregabalin Oral Solution 普瑞巴林内服溶液‌是一种用于缓解猫因运输或就诊等产生应激反应的兽用处方药，主要成分为普瑞巴林，通过作用于中枢神经系统电压门控钙通道的α2δ蛋白亚基，减少神经递质过度释放，从而发挥抗焦虑和抗应激作用。该产品为5%规格的口服溶液，猫咪接受度高。 （12）头孢维星钠注射液 Cefovecin Sodium for Injection 头孢维星钠在犬和猫皮下注射给药后吸收迅速而完全，蛋白结合率高，分别达到98.5%和99.8%。按照8mg/kg体重剂量给犬和猫进行单次皮下注射后，主要药代动力学参数分别为：峰浓度（Cmax）121µg/mL、141µg/mL；达峰时间（tmax）6.2h、2.0h；半衰期（t1/2）133h 和166h。 （13）口蹄疫病毒SAT-1型RT-PCR试剂盒             RT-PCR Kit for SAT-1 Serotype of Foot-and-Mouth Disease Virus 基于探针法实时荧光逆转录PCR（qRT-PCR）技术开发的核酸检测产品，用于定性检测水疱皮/液、OP液、血清、组织等样本中的SAT-1型口蹄疫病毒 RNA，可用于偶蹄动物SAT-1型口蹄疫的快速确诊与鉴别诊断、疫情早期筛查及隐性感染监测与流行病学调查、口岸/调运检疫、养殖场常态化防控与净化评估等。 （14）禽白血病病毒P27抗原检测试剂盒 Avian Leukosis Virus Antigen Detection Kits 针对传统禽白血病检测试剂盒灵敏度不足、变异毒株漏检率高、多亚型覆盖能力弱等行业痛点，创新采用“高亲和力重组兔单抗+多包被捕获协同夹心”核心技术将抗原最低检出限从5ng/mL降至0.5ng/mL，对ALV-K等重组毒株识别能力大幅提升。 （15）整肠泰——混合型饲料添加剂 固体 果寡糖 Ⅳ             RT-PCR Kit for SAT-1 Serotype of Foot-and-Mouth Disease Virus 原料组成果寡糖，产品成分分析保证值果寡糖 10%；水分≤10%。群体给药：禽每袋500g兑水1000～2000L，猪每袋500g拌料500～1000kg，反刍动物每袋500g拌料500～1000kg， 貂、狐、貉每袋500g拌料1000kg，水产动物每袋500g拌料500～1000kg，均可长期使用。个体给药：貂、狐、貉：每天每只0.1g，猪每10kg体重0.5～1g，可长期使用； （16）益生菌粉（犬猫通用）            Probiotic Powder 1900亿 cfu/kg高含量不虚标。嗜酸乳杆菌抑制肠道有害菌生长，调节肠道菌群平衡；酿酒酵母+维生素B群+维生素E，营养全面升级；益生菌+益生元，“双重养护”；羊乳粉+鸡肝粉，提高适口性，主动吃、不抗拒；添加3种消化酶，促进营养吸收（蛋白酶、脂肪酶、木瓜蛋白酶） （17）益生菌片（猫专用、犬专用） Probiotic Tablet 1900亿 cfu/kg 高含量不虚标。五菌联株，全面覆盖肠道需求；酿酒酵母+维生素B群，双重营养支持；益生菌+益生元，“双重养护”；鸡肝粉+蛋黄粉，提高适口性，主动吃、不抗拒；片剂设计，喂食更方便。 （18）鲨鱼软骨素片（犬猫通用）              Shark Cartilage Tablets 赛犬同款，高含量双核心关节营养，萄糖胺+鲨鱼软骨素，构建关节养护基础；六重关节养护矩阵  不止软骨素，更是全链路关节营养方案（葡萄糖胺、硫酸软骨素、绿唇贻贝、透明质酸钠、胶原蛋白、维生素D3+钙） （19）南极磷虾鱼油（犬猫通用）             Antarctic Krill & Fish Oil 南极磷虾油+鱼油双源配方，营养更丰富；DHA+EPA总含量≥250000mg/kg，高含量补充；天然维生素E抗氧化，产品稳定性更好；液体泵头设计，定量方便，拌粮简单；DHA添加，日常脑眼营养补充；磷虾油天然鲜香，适口性好。 （20）营养化毛膏   Hairball Paste 科学温和化毛，减少毛球堆积（麦芽糖+膳食纤维+圆苞车前子壳组合）；牛磺酸添加，边化毛边补充营养，维持心脏，视力健康；添加鱼油，呵护毛发健康亮泽；羊乳粉添加，适口性更好；多重维生素营养配方（维生素A，D3，E，B族维生素），全面呵护成长；多种矿物质添加（锌，铁，铜，锰），全面补充成长所需营养。 欢迎加入展商行列 拓展全球畜牧市场  共觅新商机 VIV Select China 2026 免费参观登记 即获展商名单 长按识别二维码 或点击此处（可中英文切换） 2026.移师上海 VIV SELECT CHINA 2026 亚洲国际集约化畜牧展览会（上海） >> 8月19-21日丨上海世博展览馆 International Trade show from Feed to Food 链接全球  共筑一站式畜牧商贸平台 Booth Booking·参展咨询 VIV SELECT CHINA 2027亚洲国际集约化畜牧展览会（上海） ////////// 马野 （Mr. Aason Ma） aason.ma@globusevents.com 021-6195 3565 +86-137 6165 9090 陈晓婷 （Ms. Vicky Chen） vicky.chen@globusevents.com 021-61953541 +86-138 1629 2150 虞鸥平（Mr. Matthew Yu） matthew.yu@globusevents.com 021-6195 3536 +86- 158 0083 0669 Mr.Philippe Verstuyft (based in Europe ） 海外销售 philippe@vnueurope.com +31 6 1517 3564 Mr.Umberto Cioffi  (based in Europe ） 海外销售 umberto@vnueurope.com +31 6 1188 8084 ////////// 张娅坪（Ms. Gemma Zhang） 市场宣传/会议合作 gemma.zhang@globusevents.com 021-61956095 +86- 136 6153 9222 胡颖（Ms. Carolyn Hu ） 市场宣传/会议合作 carolyn.hu@globusevents.com 021-61953516 +86- 159 2146 1780 白 雪（Ms. Snow Bai） 市场宣传/会议合作 snow.bai@globusevents.com 021-61953554 +86- 139 1737 2737 郝永丽（Ms. Well Hao） 商务合作 well.hao@globusevents.com 021-6195 6015 +86- 135 2468 9191 International Trade Show From Feed to Food 链接全球  共筑一站式畜牧商贸平台 WWW.VIVWORLDWIDE.CN